Retrospective Study Of The Influence Of Age At Start Of Growth Hormone Treatment On Height Gain In Children Born Small for Gestational Age
NCT ID: NCT01897753
Last Updated: 2014-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
264 participants
OBSERVATIONAL
2012-03-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age
NCT00557336
Follow-up to Adult Height of a Cohort of Subjects Born Small for the Gestational Age and Treated With Growth Hormone
NCT01196156
Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years
NCT00184691
Efficacy on Height in SGA Children Treated With Growth Hormone
NCT00184756
Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)
NCT01859949
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Small For Gestational Age (SGA) Children
SGA children under growth hormone treatment for more than 36 months.
growth hormone
36 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
growth hormone
36 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treated with GH at least 36 months.
Exclusion Criteria
4 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
H. Germans Trias i Pujol
Badalona, Barcelona, Spain
Capio H.Universitario Sagrat Cor
Barcelona, Barcelona, Spain
H. Vall d'Hebron
Barcelona, Barcelona, Spain
H. Sant Joan de Déu
Esplugues de Llobregat, Barcelona, Spain
H.Marqués de Valdecilla
Santander, Cantabria, Spain
H.Gregorio Marañón
Madrid, Madrid, Spain
Hospital La Paz
Madrid, Madrid, Spain
Hospital Virgen de la Arrixaca
El Palmar, Murcia, Spain
Hospital Carlos Haya
Málaga, Málaga, Spain
Hospital Virgen del Camino
Pamplona, Navarre, Spain
H.Clinico Universitario Valladolid
Valladolid, Valladolid, Spain
Hospital Universitario Miguel Servet
Zaragoza, Zaragoza, Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6281310
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.